💬In plain words
What the trial is, and whether it could suit you
The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Histology or cytologically confirmed mature B-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
* Able to comply with scheduled follow-up and with management of toxicity
* Signed informed consent
Exclusion Criteria:
* Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
* Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
* Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.
Exclusion Criteria related to Rituximab :
* Tumor cell negative for CD20
* Prior exposure to rituximab
* Hepatitis B carrier status history of HBV or positive serology.
💊
What it tests
- Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
- Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
- Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
- Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
- Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone
Shanghai Children's Medical Center
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky